The cross-sectional association between vasomotor symptoms and hemostatic parameter levels in postmenopausal women

Laura B. Harrington, Marc Blondon, Mary Cushman, Andrew M. Kaunitz, Jacques E. Rossouw, Matthew A. Allison, Lisa W. Martin, Karen Johnson, Jan Rosing, Nancy F. Woods, Andrea Z. LaCroix, Susan R. Heckbert, Barbara McKnight, Nicholas L. Smith

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: Vasomotor symptoms (VMS) may be a marker of cardiovascular risk. We aimed to evaluate the cross-sectional association of VMS presence and severity with hemostatic parameter levels measured at baseline among Women's Health Initiative (WHI) Hormone Therapy trial postmenopausal participants. Methods: This cross-sectional analysis included 2,148 postmenopausal women with measures of VMS presence and severity reported in the 4 weeks before WHI baseline, who were not using warfarin or hormone therapy and for whom the following baseline hemostatic parameters were measured within the WHI Cardiovascular Disease Biomarker Case-Control Study: antithrombin, plasminogen activator inhibitor-1, protein C antigen, total and free protein S antigen, total and free tissue factor pathway inhibitor, D-dimer, normalized activated protein C sensitivity ratio, and thrombin generation. Using multiple linear regression, we estimated the adjusted average difference in each hemostatic parameter associated with VMS presence and severity. A multiple comparisons-corrected P value was computed using the P-min procedure to determine statistical significance of our smallest observed P value. Results: Women were 67 years of age on average and 33% reported VMS presence at baseline. There was some suggestion that VMS presence may be associated with a - 0.34 adjusted difference in normalized activated protein C sensitivity ratio compared with no VMS (95% CI, - 0.60 to - 0.087; P = 0.009), but this association was not significant after correction for multiple comparisons (P = 0.073). VMS presence or severity was not significantly associated with the other hemostatic parameters. Conclusions: We found no convincing evidence that VMS presence or severity was associated with levels of hemostatic parameters among postmenopausal women.

Original languageEnglish (US)
Pages (from-to)360-370
Number of pages11
JournalMenopause
Volume24
Issue number4
DOIs
StatePublished - Jan 1 2017

Fingerprint

Hemostatics
Women's Health
Protein C
Replication Protein C
Hormones
Antigens
Antithrombins
Protein S
Plasminogen Activator Inhibitor 1
Warfarin
Thrombin
Case-Control Studies
Linear Models
Cardiovascular Diseases
Cross-Sectional Studies
Biomarkers
Therapeutics

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this

Harrington, L. B., Blondon, M., Cushman, M., Kaunitz, A. M., Rossouw, J. E., Allison, M. A., ... Smith, N. L. (2017). The cross-sectional association between vasomotor symptoms and hemostatic parameter levels in postmenopausal women. Menopause, 24(4), 360-370. https://doi.org/10.1097/GME.0000000000000777

The cross-sectional association between vasomotor symptoms and hemostatic parameter levels in postmenopausal women. / Harrington, Laura B.; Blondon, Marc; Cushman, Mary; Kaunitz, Andrew M.; Rossouw, Jacques E.; Allison, Matthew A.; Martin, Lisa W.; Johnson, Karen; Rosing, Jan; Woods, Nancy F.; LaCroix, Andrea Z.; Heckbert, Susan R.; McKnight, Barbara; Smith, Nicholas L.

In: Menopause, Vol. 24, No. 4, 01.01.2017, p. 360-370.

Research output: Contribution to journalArticle

Harrington, LB, Blondon, M, Cushman, M, Kaunitz, AM, Rossouw, JE, Allison, MA, Martin, LW, Johnson, K, Rosing, J, Woods, NF, LaCroix, AZ, Heckbert, SR, McKnight, B & Smith, NL 2017, 'The cross-sectional association between vasomotor symptoms and hemostatic parameter levels in postmenopausal women', Menopause, vol. 24, no. 4, pp. 360-370. https://doi.org/10.1097/GME.0000000000000777
Harrington, Laura B. ; Blondon, Marc ; Cushman, Mary ; Kaunitz, Andrew M. ; Rossouw, Jacques E. ; Allison, Matthew A. ; Martin, Lisa W. ; Johnson, Karen ; Rosing, Jan ; Woods, Nancy F. ; LaCroix, Andrea Z. ; Heckbert, Susan R. ; McKnight, Barbara ; Smith, Nicholas L. / The cross-sectional association between vasomotor symptoms and hemostatic parameter levels in postmenopausal women. In: Menopause. 2017 ; Vol. 24, No. 4. pp. 360-370.
@article{cd35bf4b198b4b10af9a6427cb2ef8a1,
title = "The cross-sectional association between vasomotor symptoms and hemostatic parameter levels in postmenopausal women",
abstract = "Objective: Vasomotor symptoms (VMS) may be a marker of cardiovascular risk. We aimed to evaluate the cross-sectional association of VMS presence and severity with hemostatic parameter levels measured at baseline among Women's Health Initiative (WHI) Hormone Therapy trial postmenopausal participants. Methods: This cross-sectional analysis included 2,148 postmenopausal women with measures of VMS presence and severity reported in the 4 weeks before WHI baseline, who were not using warfarin or hormone therapy and for whom the following baseline hemostatic parameters were measured within the WHI Cardiovascular Disease Biomarker Case-Control Study: antithrombin, plasminogen activator inhibitor-1, protein C antigen, total and free protein S antigen, total and free tissue factor pathway inhibitor, D-dimer, normalized activated protein C sensitivity ratio, and thrombin generation. Using multiple linear regression, we estimated the adjusted average difference in each hemostatic parameter associated with VMS presence and severity. A multiple comparisons-corrected P value was computed using the P-min procedure to determine statistical significance of our smallest observed P value. Results: Women were 67 years of age on average and 33{\%} reported VMS presence at baseline. There was some suggestion that VMS presence may be associated with a - 0.34 adjusted difference in normalized activated protein C sensitivity ratio compared with no VMS (95{\%} CI, - 0.60 to - 0.087; P = 0.009), but this association was not significant after correction for multiple comparisons (P = 0.073). VMS presence or severity was not significantly associated with the other hemostatic parameters. Conclusions: We found no convincing evidence that VMS presence or severity was associated with levels of hemostatic parameters among postmenopausal women.",
author = "Harrington, {Laura B.} and Marc Blondon and Mary Cushman and Kaunitz, {Andrew M.} and Rossouw, {Jacques E.} and Allison, {Matthew A.} and Martin, {Lisa W.} and Karen Johnson and Jan Rosing and Woods, {Nancy F.} and LaCroix, {Andrea Z.} and Heckbert, {Susan R.} and Barbara McKnight and Smith, {Nicholas L.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/GME.0000000000000777",
language = "English (US)",
volume = "24",
pages = "360--370",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - The cross-sectional association between vasomotor symptoms and hemostatic parameter levels in postmenopausal women

AU - Harrington, Laura B.

AU - Blondon, Marc

AU - Cushman, Mary

AU - Kaunitz, Andrew M.

AU - Rossouw, Jacques E.

AU - Allison, Matthew A.

AU - Martin, Lisa W.

AU - Johnson, Karen

AU - Rosing, Jan

AU - Woods, Nancy F.

AU - LaCroix, Andrea Z.

AU - Heckbert, Susan R.

AU - McKnight, Barbara

AU - Smith, Nicholas L.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objective: Vasomotor symptoms (VMS) may be a marker of cardiovascular risk. We aimed to evaluate the cross-sectional association of VMS presence and severity with hemostatic parameter levels measured at baseline among Women's Health Initiative (WHI) Hormone Therapy trial postmenopausal participants. Methods: This cross-sectional analysis included 2,148 postmenopausal women with measures of VMS presence and severity reported in the 4 weeks before WHI baseline, who were not using warfarin or hormone therapy and for whom the following baseline hemostatic parameters were measured within the WHI Cardiovascular Disease Biomarker Case-Control Study: antithrombin, plasminogen activator inhibitor-1, protein C antigen, total and free protein S antigen, total and free tissue factor pathway inhibitor, D-dimer, normalized activated protein C sensitivity ratio, and thrombin generation. Using multiple linear regression, we estimated the adjusted average difference in each hemostatic parameter associated with VMS presence and severity. A multiple comparisons-corrected P value was computed using the P-min procedure to determine statistical significance of our smallest observed P value. Results: Women were 67 years of age on average and 33% reported VMS presence at baseline. There was some suggestion that VMS presence may be associated with a - 0.34 adjusted difference in normalized activated protein C sensitivity ratio compared with no VMS (95% CI, - 0.60 to - 0.087; P = 0.009), but this association was not significant after correction for multiple comparisons (P = 0.073). VMS presence or severity was not significantly associated with the other hemostatic parameters. Conclusions: We found no convincing evidence that VMS presence or severity was associated with levels of hemostatic parameters among postmenopausal women.

AB - Objective: Vasomotor symptoms (VMS) may be a marker of cardiovascular risk. We aimed to evaluate the cross-sectional association of VMS presence and severity with hemostatic parameter levels measured at baseline among Women's Health Initiative (WHI) Hormone Therapy trial postmenopausal participants. Methods: This cross-sectional analysis included 2,148 postmenopausal women with measures of VMS presence and severity reported in the 4 weeks before WHI baseline, who were not using warfarin or hormone therapy and for whom the following baseline hemostatic parameters were measured within the WHI Cardiovascular Disease Biomarker Case-Control Study: antithrombin, plasminogen activator inhibitor-1, protein C antigen, total and free protein S antigen, total and free tissue factor pathway inhibitor, D-dimer, normalized activated protein C sensitivity ratio, and thrombin generation. Using multiple linear regression, we estimated the adjusted average difference in each hemostatic parameter associated with VMS presence and severity. A multiple comparisons-corrected P value was computed using the P-min procedure to determine statistical significance of our smallest observed P value. Results: Women were 67 years of age on average and 33% reported VMS presence at baseline. There was some suggestion that VMS presence may be associated with a - 0.34 adjusted difference in normalized activated protein C sensitivity ratio compared with no VMS (95% CI, - 0.60 to - 0.087; P = 0.009), but this association was not significant after correction for multiple comparisons (P = 0.073). VMS presence or severity was not significantly associated with the other hemostatic parameters. Conclusions: We found no convincing evidence that VMS presence or severity was associated with levels of hemostatic parameters among postmenopausal women.

UR - http://www.scopus.com/inward/record.url?scp=85002412665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85002412665&partnerID=8YFLogxK

U2 - 10.1097/GME.0000000000000777

DO - 10.1097/GME.0000000000000777

M3 - Article

VL - 24

SP - 360

EP - 370

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 4

ER -